Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

The oral LD50 of the test item, Fenethylpivalinate, is higher than 5000 ml/kg bw in rats therefore it is not classified according to the Annex VI to the Directive 67/548/EEC and the CLP Regulation (EC) N° (1272-2008).

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
1981
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Study conducted similarly to OECD Guideline 401 with deviations: no data about purity and no certificate of analysis of test substance; bodyweight changes were not reported
Reason / purpose for cross-reference:
reference to same study
Reason / purpose for cross-reference:
reference to other study
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
Deviations:
yes
Remarks:
no data about purity and no certificate of analysis of test substance; bodyweight changes were not reported
Principles of method if other than guideline:
Not applicable
GLP compliance:
no
Remarks:
pre-GLP
Test type:
standard acute method
Limit test:
yes
Species:
rat
Strain:
other: SPF albino
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Age at study initiation: Young adult
- Source: Central Institute for the Breading of Laboratory Animals TNO, Zeist, The Netherlands
- Weight at study initiation: Males: 156-240 g; females: 136-176 g
- Housing: Animals were housed in groups of five in screen-bottomed stainless steel cages.
- Fasting period before study: Overnight
- Diet: Stock diet, ad libitum
- Water: Tap water, ad libitum

ENVIRONMENTAL CONDITIONS
- Temperature: 23 ± 1 °C
- Ventilation: Well-ventilated room
Route of administration:
oral: unspecified
Vehicle:
unchanged (no vehicle)
Details on oral exposure:
MAXIMUM DOSE VOLUME ADMINISTERED: 5 mL/kg bw
Doses:
5 mL/kg bw
No. of animals per sex per dose:
10
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Necropsy of survivors performed: Yes
Statistics:
None
Preliminary study:
Not applicable
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 5 mL/kg bw
Based on:
test mat.
Remarks on result:
other: equivalent to 4950 mg/kg bw; calculated using the density of 0.99 g/L (literature)
Mortality:
- 3/10 females died between Days 2 and 4 after treatment.
Clinical signs:
other: - Sedation and ataxia were observed within a few hours after treatment and persisted for a few days. - All survivors recovered gradually and appeared healthy at the end of the observation period.
Gross pathology:
- Gross observations at necropsy were normal for all of the surviving animals.
Other findings:
None

None

Interpretation of results:
not classified
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
The oral LD50 of the test item, Fenethylpivalinate, is higher than 2000 mg/kg bw in rats and therefore it is not classified according to the Annex VI to the Directive 67/548/EEC and the CLP Regulation (EC) N° (1272-2008).
Executive summary:

In an acute oral toxicity study performed similarly to OECD Guideline 401, 10 male and 10 female rats of SPF strain were given a single oral dose of the test item, Fenethylpivalinate, at 5 mL/kg bw. Animals were then observed for mortality and clinical signs for 14 days and all survivors were macroscopically necropsied after sacrifice.

Three females died between Days 2 and 4 after treatment. Sedation and ataxia were observed within a few hours after treatment and persisted for a few days. All survivors recovered gradually and appeared healthy at the end of the observation period. Surviving animals presented a normal appearance at autopsy. In this study, the combined oral LD50 of the test item, Fenethylpivalinate, in rats was considered to be greater than 5 mL/kg.

The oral LD50 of the test item, Fenethylpivalinate, is higher than 5000 ml/kg bw in rats therefore it is not classified according to the Annex VI to the Directive 67/548/EEC and the CLP Regulation (EC) N° (1272-2008).

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
2 000 mg/kg bw
Quality of whole database:
Acceptable

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Justification for selection of acute toxicity – oral endpoint
Good quality study, to GLP.

Justification for classification or non-classification

Based on the result of a reliable Acute Oral Toxicity test in rats, calssification under the EU DSD or CLP regulations as acutely toxic by the oral route is not required.

Categories Display